ANVISA opened an investigation into 13 reported cases of NAION optic nerve disease in GLP-1 medication users. Here's what the current evidence shows and what patients should know.
The Investigation Begins: What Started This Review
Brazil's health regulatory agency ANVISA officially opened a formal investigation into 13 reported cases of eye disease in patients using GLP-1 medications, primarily Ozempic (semaglutide). The cases involve a specific optic nerve condition called NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy), which can lead to vision loss. Ozempic received ANVISA approval in Brazil on January 25, 2018, and the agency began receiving adverse event reports that prompted this safety review. For those following GLP-1 medication developments, the OzemNews team has been tracking these investigations as new information emerges.
What Is NAION and Why Does It Matter
NAION occurs when blood flow to the optic nerve head is reduced, causing ischemic damage that is typically permanent. Clinically, patients experience painless vision loss, often noticed upon waking, affecting one eye initially. The condition represents one of the most common causes of optic nerve-related blindness in adults.
Baseline incidence of NAION in the general population ranges from 2.3 to 10.3 per 100,000 persons annually, according to ophthalmology literature. This baseline matters because establishing whether a medication connection exists requires careful statistical analysis, especially given that certain underlying conditions already increase NAION risk.
Type 2 diabetes itself increases NAION risk by 2 to 4 times compared to the non-diabetic population, according to diabetes and ophthalmology journals. This creates a confounding factor when evaluating reports from patients using semaglutide, since many GLP-1 users have type 2 diabetes.
What the Scientific Literature Shows
A study published in JAMA Ophthalmology found approximately 4 times higher risk of NAION in semaglutide-treated patients compared to controls. However, researchers emphasize that observational data has significant limitations. Correlation does not equal causation at this stage, and the biological mechanism linking GLP-1 receptor activation to optic nerve damage remains unclear.
What scientists still do not know is whether semaglutide directly affects optic nerve blood vessels, whether rapid metabolic changes play a role, or whether the underlying conditions being treated (obesity and diabetes) are primarily responsible for the observed signal.
How Other Regulatory Agencies Are Responding
The FDA has received reports of vision disorders including NAION in connection with semaglutide, according to FDA FAERS data. The agency has issued labeling updates for Ozempic and Wegovy regarding vision-related adverse events. Meanwhile, the EMA publishes periodic safety updates for GLP-1 receptor agonists, maintaining ongoing surveillance across the European Union.
When comparing case numbers across agencies relative to population exposure, the numbers remain relatively small given the millions of patients worldwide using these medications. This cross-regulatory context suggests the evidence, while worth investigating seriously, has not yet reached the threshold for stronger regulatory action. The OzemNews will continue monitoring updates from these agencies as they publish new safety communications.
Risk Factors Emerging From the Data
Several patterns emerge when examining reported cases. Patients with pre-existing diabetes appear frequently among NAION reports, though researchers continue assessing whether the disease or its treatment drives this association. Hypertension and cardiovascular history also show up commonly, suggesting these conditions may act as risk amplifiers.
Rapid weight loss has been independently associated with vision changes in medical literature. Since many GLP-1 users experience significant weight reduction, this factor requires further investigation as a potential contributor to optic nerve stress.
What Patients Should Consider Now
Medical professionals strongly advise against discontinuing GLP-1 medications without consulting a prescribing doctor. Stopping treatment abruptly may pose greater risks than continuing, particularly for patients with diabetes or cardiovascular conditions.
Symptoms warranting immediate medical evaluation include sudden vision loss, blurred vision, difficulty seeing colors, or any changes in visual acuity, regardless of how long someone has been taking the medication. Early intervention matters when it comes to preserving vision.
Patients with multiple risk factors, personal history of optic nerve conditions, or family history of NAION should discuss baseline ophthalmologic assessment with their doctor. These conversations should happen at prescribing appointments, not after symptoms appear.
Where This Investigation Goes From Here
ANVISA uses WHO-UMC criteria to evaluate causality in adverse event reports, a standardized framework that assigns probability levels from unlikely to certain. The agency will continue collecting case reports and monitoring international developments before determining whether label updates become necessary.
Ongoing clinical studies specifically designed to evaluate vision outcomes in GLP-1 treated patients may provide clearer answers within the next several years. Until then, sustained pharmacovigilance matters more than alarm. The OzemNews team will continue reporting on these findings as new information becomes available at https://ozemnews.com.
FAQ
Should I stop taking Ozempic if I'm concerned about vision problems?
No. Never discontinue prescribed medications without consulting your doctor first. Contact your healthcare provider to discuss your specific risk factors and whether any additional monitoring is appropriate for your situation.
What are the warning signs of NAION I should watch for?
NAION typically presents as sudden, painless vision loss, often noticed upon waking. You might experience blurry vision, difficulty seeing colors, or a dark area in your visual field. If any of these occur, seek medical attention immediately.
Does having diabetes mean I cannot use GLP-1 medications safely?
Not necessarily. Type 2 diabetes increases NAION risk, but this does not mean GLP-1 medications are contraindicated. Your doctor can help weigh benefits against potential risks based on your complete medical history and current health status.
How many NAION cases have actually been reported with Ozempic?
ANVISA officially received 13 reports as of the investigation opening. This number reflects suspected cases, not confirmed cases, and must be interpreted alongside the millions of patients using these medications worldwide.
Sources
Disclaimer: This content is for informational purposes only and does not replace professional medical advice. Always consult your doctor before starting, changing or stopping any treatment.
Ozempro — Monitor GLP-1
Track your weight and your progress
Log weight, measurements and labs and see your progress in clear charts — because progress you don't measure is invisible progress.
or download the app